The kidney and bone metabolism: Nephrologists' point of view

Journal of Bone and Mineral Metabolism

Volumn 24, Issue 6, 2006, Pages 434-438

  Fukagawa, Masafumi ^a   Hamada, Yasuhiro ^a   Nakanishi, Shohei ^a,b   Tanaka, Motoko ^c  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c Akebono Clinic   (Japan)

Author keywords

Chronic kidney disease; CKD MBD; FGF23; Indoxyl sulfate; Kidney; Parathyroid; PTH

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; INDICAN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

AGING; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE METABOLISM; CALCIFICATION; CHRONIC KIDNEY DISEASE; DIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; KIDNEY DISEASE; KIDNEY METABOLISM; MALNUTRITION; MENOPAUSE; METASTASIS; MINERAL METABOLISM; NEPHROLOGIST; NODULAR HYPERPLASIA; NONHUMAN; OSTEOBLAST; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; UREMIA;

ANIMALS; BONE AND BONES; HUMANS; KIDNEY; KIDNEY DISEASES; MINERALS; NEPHROLOGY; PARATHYROID HORMONE;

EID: 33750528942     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-006-0719-7     Document Type: Review

References (70)

1. M Fukagawa T Akizawa 2006 Calcium abnormalities of dialysis patients J Bone Miner Metab 24 160
2. H Malluche MC Faugere 1990 Renal bone disease 1990: an unmet challenge for the nephrologists Kidney Int 38 193 211
3. Patient Registration Committee, Japanese Society for Dialysis Therapy 2005 An Overview of regular dialysis treatment in Japan as of 31 December 2003 Ther Apher Dial 9 431 458
4. WG Goodman J Goldin BD Kuison C Yoon B Gales D Sider Y Wang J Chung A Emerick L Greaser RM Elashoff IB Salusky 2003 Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis N Engl J Med 342 1478 1483
5. S Moe T Drueke J Cunningham W Goodman K Martin K Olgaard S Ott S Sprague N Lameire G Eknoyan Kidney Disease: Improving Global Outcome (KDIGO) 2006 Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcome (KDIGO) Kidney Int 69 1945 1953
6. K Olgaard E Lewin 2006 Can hyperparathyroid bone disease be arrested or reversed? Clin J Am Soc Nephrol 1 367 373
7. E Slatopolsky S Caglar L Gradowska J Canturbury E Reiss NS Bricker 1972 On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake Kidney Int 2 147 151
8. E Slatopolsky J Finch M Denda C Ritter M Zhong A Dusso PN [tmp] MacDonald AJ Brown 1996 Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro J Clin Invest 97 2534 2540
9. AA Portale BE Booth BP Halloran RC Morris Jr 1984 Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency J Clin Invest 73 1580 1589
10. T Shigematsu JJ Kazama T Yamashita S Fukumoto T Hosoya F Gejyo M Fukagawa 2004 Possible involvement of circulating fibroblast growth factor-23 in the development of secondary hyperparathyroidism associated with renal insufficiency Am J Kidney Dis 44 250 256
11. M Fukagawa S Nakanishi JJ Kazama 2006 Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease Kidney Int 70 Suppl 102 S3 S7
12. TB Drüeke 2000 Cell biology of parathyroid gland hyperplasia in chronic renal failure J Am Soc Nephrol 11 1141 1152
13. Y Tominaga Y Tanaka K Sato T Nagasaka H Takagi 1997 Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism Semin Surg Oncol 13 78 86
14. N Fukuda H Tanaka Y Tominaga M Fukagawa K Kurokawa Y Seino 1993 Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients J Clin Invest 92 1436 1443
15. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism J Clin Endocrinol Metab 81 1598 1606
16. Y Tominaga S Kohara Y Namii T Nagasaka T Haba K Uchida M Numano Y Tanaka H Takagi 1996 Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism World J Surg 20 744 750
17. M Cozzolino Y Lu T Sato J Yang IG Suarez D Brancaccio E Slatopolsky A Dusso 2005 A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease Am J Physiol Renal Physiol 289 F1096 F1102
18. A Dusso T Sato MV Arcidiacono DA Hernandez J Yang I Gonzarez-Suarez Y Tominaga E Slatopolsky 2006 Pathogenic mechanisms for parathyroid hyperplasia Kidney Int 70 Suppl 102 S8 S11
19. National Kidney Foundation 2003 K/DOQI Clinical guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 Suppl 3 S1 S202
20. M Fukagawa M Kitaoka H Yi N Fukuda T Matsumoto E Ogata M Kitaoka S Harada NM Sekine T Matsumoto K Kurokawa 1994 Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patient Nephron 68 221 228
21. N Kato M Nakayama T Shigematsu H Yamamoto K Sano I Saito H Nakano K Kasai H Kubo S Sakai Y Kawaguchi T Hosoya 2000 Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism Am J Kidney Dis 35 4665 468
22. S Okuno E Ishimura K Kitatani H Chou K Nagasue K Maekawa T Izumotani T Yamakawa Y Imanishi T Shoji M Inaba Y Nishizawa 2003 Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism Nephrol Dial Transplant 18 2613 2621
23. Y Tominaga D Inaguma S Matsuoka H Tahara K Kukita S Kurihara N Onoda Y Tsuruta S Tsutsui K Ohta M Kuwahara M Tanaka Y Nishizawa PTG study group 2006 Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism Ther Apher Dial 10 198 204
24. N Onoda S Kurihara Y Sakurai K Owada E Osono H Adachi M Suga H Yoneshima 2003 Evaluation of blood supply to parathyroid glands in secondary hyperparathyroidism compared with histopathology Nephrol Dial Transplant 18 Suppl 3 iii34 iii37
25. M Nakamura S Fuchinoue S Teraoka 2003 Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism Am J Kidney Dis 42 739 745
26. T Shimada S Mizutani T Muto T Yoneya R Hino S Takeda Y Takeuchi T Fujita S Fukumoto T Yamashita 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia Proc Natl Acad Sci USA 98 6500 6505
27. M Fukagawa JJ Kazama 2005 Editorial comments: With or without the kidney: the role of FGF23 in CKD Nephrol Dial Transplant 20 1295 1298
28. S Nakanishi JJ Kazama T Nii-Kono K Omori T Yamashita S Fukumoto F Gejyo T Shigematsu M Fukagawa 2005 Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients Kidney Int 67 1171 1178
29. JJ Kazama F Sato K Omori H Hama S Yamamoto H Maruyama I Narita F Gejyo T Yamashita S Fukumoto M Fukagawa 2005 Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients Kidney Int 67 1120 1125
30. H Nishi T Nii-Kono S Nakanishi Y Yamazaki T Yamashita S Fukumoto K Ikeda A Fujimori M Fukagawa 2005 Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism Nephron Clin Pract 101 c94 c99
31. H Kurosu Y Ogawa M Miyoshi M Yamamoto A Nandi KP Rosenblatt MG Baum S Schiavi MC Hu OW Moe M Kuro-o 2006 Regulation of fibroblast growh factor-23 signalling by klotho J Biol Chem 281 6120 6123
32. RC Brown JP Aston I Weeks JS Woodhead 1987 Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay J Clin Endocrinol Metab 65 407 414
33. MR John WG Goodman P Gao TL Cantor IB Salusky H Juppner 1999 A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure J Clin Endocrinol Metab 84 4287 4290
34. S Nakanishi JJ Kazama T Shigematsu Y Iwasaki TL Cantor T Kurosawa M Fukagawa 2001 Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients Am J Kidney Dis 38 Suppl 1 S172 174
35. M Tanaka K Itoh K Matsushita K Matsushita H Fujii M Fukagawa 2005 Normalization of reversed bio-intact-PTH(1-84)/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism Clin Nephrol 64 69 72
36. T Arakawa D'Amour M Sakai H Katsumoto N Igaki T Goto T Cantor M Fukagawa 2006 Production and secretion of a novel molecular form of PTH from the most severe type of parathyroid hyperplasia in uremia Clin J Am Soc Nephrol 1 525 531
37. P D'Amour JH Brossard L Rousseau L Roy P Gao T Cantor 2003 Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism Clin Chem 49 2037 2044
38. A Rakel JH Brossard J-V Patenaude C Albert E Nassif T Cantor L Rousseau P D'Amour 2005 Overproduction of an amino-terminal form of PTH distinct from human PTH (1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery Clin Endocrinol 62 721 727
39. M Fukagawa JJ Kazama T Shigematsu 2002 Management of the patients with advanced secondary hyperparathyroidism: the Japanese approach Nephrol Dial Transplant 17 1553 1557
40. M Tanaka Y Tominaga E Sawatari K Itoh K Matsushita K Matsushita S Matsuoka T Ueki N Goto T Sato A Katayama T Haba K Uchida 2004 Infarction of mediastinal parathyroid gland causing spontaneous remission of secondary hyperparathyroidism Am J Kidney Dis 44 762 767
41. M Tanaka Y Tominaga K Itoh K Matsushita K Matsushita T Ueki N Goto T Sato A Kanayama T Haba K Uchida 2006 Autoinfarction of the parathyroid gland diagnosed by power Doppler ultrasonography in a patient with secondary hyperparathyroidism Nephrol Dial Transplant 21 1092 1095
42. M Fukagawa M Kitaoka Y Tominaga T Akizawa T Kakuta N Onoda F Koiwa S Yumita K Kurokawa Japanese Society for Parathyroid Intervention 2003 Guideline for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients Nephrol Dial Transplant 18 Suppl 3 31 33
43. M Kitaoka M Fukagawa E Ogata K Kurokawa 1994 Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients Kidney Int 46 1110 1117
44. T Kakuta M Fukagawa T Fujisaki M Hida H Suzuki H Sakai K Kurokawa A Saito 1999 Prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients Am J Kidney Dis 33 1091 1099
45. M Kitaoka M Fukagawa N Fukuda H Yi K Kurokawa 1995 Direct injections of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction Nephrology 1 563 568
46. M Kitaoka N Onoda H Kitamura F Koiwa M Tanaka M Fukagawa 2003 Percutaneous calcitriol injection therapy (PCIT) of secondary hyperparathyroidism: multicentre trial Nephrol Dial Transplant 18 Suppl 3 38 41
47. K Shiizaki I Hatamura S Negi N Narukawa M Mizobuchi T Sakaguchi A Ooshima T Akizawa 2003 Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia Kidney Int 64 992 1003
48. K Shiizaki S Negi I Hatamura T Sakaguchi F Sagi K Kunimoto M Mizobuchi I Imazeki A Ooshima T Akizawa 2005 Biochemical and cellular effect of direct maxacalcitol injection into parathyroid gland in uremic rat J Am Soc Nephrol 16 97 108
49. M Colloton E Shatzen G Miller C Stehman-Breen M Wada D Lacey D Martin 2005 Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism Kidney Int 67 467 476
50. M Fukagawa 2006 Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism? Nat Clin Pract Nephrol 2 248 249
51. TR Srinivas JD Schold KL Womer B Kaplan RJ Howard CM Bucci H Meier-Kriesche 2006 Improvement in hypercalcemia with cinacalcet after kidney transplantation Clin J Am Soc Nephrol 1 323 326
52. SG Massry JW Coburn DB Lee J Jowsey CR Kleeman 1973 Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects Ann Intern Med 78 357 364
53. M Fukagawa JJ Kazama T Shigematsu 2001 Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases Am J Kidney Dis 38 S152 S155
54. DJ Sherrard G Hercz Y Pei NA Maloney C Greenwood A Manuel C Saiphoo SS Fenton GV Segre 1993 The spectrum of bone disease in end-stage renal failure-an evolving disorder Kidney Int 43 436 442
55. WG Goodman JA Ramirez TR Belin Y Chon B Gales GV Segre IB Salusky 1994 Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy Kidney Int 46 1160 1166
56. K Atsumi K Kushida K Yamazaki S Shimizu A Ohmura T Inoue 1999 Risk factors for vertebral fractures in renal osteodystrophy Am J Kidney Dis 33 287 293
57. M Coco H Rush 2000 Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone Am J Kidney Dis 36 1115 1121
58. P Kurz MC Monier-Faugere B Bognar E Werner P Roth J Vlachojannis HH Malluche 1994 Evidence for abnormal calcium homeostasis in patients with adynamic bone disease Kidney Int 46 855 861
59. LD Quarles B Lobaugh G Murphy 1992 Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia J Clin Endocrinol Metab 75 145 150
60. MC Monier-Faugere Z Geng H Mawad RM Friedler P Gao TL Cantor HH Malluche 2001 Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients Kidney Int 60 1460 1468
61. P Friedman WG Goodman 2006 PTH (1-84)/PTH (7-84): a balance of power Am J Physiol Renal Physiol 290 F975 F984
62. RJ Lund MR Davies AJ Brown KA Hruska 2004 Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model J Am Soc Nephrol 15 359 369
63. Y Iwasaki-Ishizuka H Yamato T Nii-Kono A Fujieda M Uchida A Hosokawa M Motojima K Kurokawa M Fukagawa 2005 Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of chronic renal failure with low turnover bone Nephrol Dial Transplant 20 1904 1911
64. R Vanholder RD Smet G Glorieux A Argiles U Baurmeiter European Uremic Toxin Work Group (EUTox) 2003 Review on uremic toxins: classification, concentration, and interindividual variability Kidney Int 63 1934 1943
65. Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M (2006) Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uremic rats. Nephrol Dial Transplant doi:10.1093/ndt/gfl311
66. A Enomoto M Takeda A Tojo T Sekine SH Cha S Khamdang F Takayama I Aoyama S Nakayama H Endou T Niwa 2002 Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity J Am Soc Nephrol 13 1711 1720
67. WJ Boyle WS Simonet DL Lacey 2003 Osteoclast differentiation and activation Nature 423 337 342
68. JJ Kazama T Shigematsu E Tsuda K Yano M Miura Y Kawaguchi F Gejyo K Kurokawa M Fukagawa 2002 Increased circulating levels of osteoclastogenesis inhibitory factor/osteoprotegerin in patients with chronic renal failure: possible roles in skeletal resistance to PTH in uremia Am J Kidney Dis 39 525 532
69. JJ Kazama K Omori S Yamamoto Y Ito H Maruyami I Narita F Gejyo Y Iwasaki M Fukagawa 2006 Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism Ther Apher Dial 10 262 266
70. M Tanaka K Itoh K Matsushita K Matsushita M Fukagawa 2005 High serum estradiol concentrations in postmenopausal women with end-stage renal disease (letter) Clin Nephrol 64 394 396